论文部分内容阅读
目的 通过 12 4例慢重肝临床分析对目前慢重肝治疗疗效、临床特点、治疗难点作一简要分析。方法 对12 4例慢重肝进行病原分型、临床分期、分组治疗及疗效判定。结果 1早、中期慢重肝疗效较晚期者显著性差异 (P<0 .0 5 )。 2早、中期慢重肝病死率较晚期者有显著性差异 (P<0 .0 5 )。 3分组治疗病死率无显著性差异 (P>0 .0 5 )。 4死亡组与存活组病例 TB、AL B、PTA有显著性差异 (P<0 .0 5 )。结论 1早、中期慢重肝疗效优于晚期者、病死率也较晚期低。 2慢重肝治疗无特效药物。 3 TB、AL B、PTA对慢性重肝患者预后判定有一定价值
Objective To provide a brief analysis of the curative effect, clinical features and treatment difficulties of 124 patients with chronic liver diseases by clinical analysis of 124 patients with chronic liver diseases. Methods One hundred and twenty-four patients with chronic severe hepatitis were divided into two groups according to their pathogenicity, clinical stage, grouping and curative effect. Results 1 Early and mid-term chronic severe hepatitis were significantly different (P <0. 05). 2 Early and mid-term chronic severe hepatitis mortality were significantly different (P <0. 05). There was no significant difference between the three groups in the treatment of mortality (P> 0.05). There was a significant difference between 4 death group and survival group TB, AL B, PTA (P <0.05). Conclusions 1 Early and mid-term chronic severe hepatitis have better curative effect than the late stage, and the mortality is lower than the late stage. 2 slow liver treatment of non-specific drugs. 3 TB, AL B, PTA have a certain value in the prognosis of patients with chronic severe hepatitis